19788-36-4 Usage
General Description
(3,5-Dimethyl-4-isoxazolyl)methanol, also known as DMOM, is a chemical compound with the molecular formula C7H9NO2. It is a white to off-white crystalline solid that is commonly used as a building block in organic synthesis. DMOM is often used as a reagent in the synthesis of pharmaceuticals and agrochemicals, as well as in the production of fragrances and flavors. It has been reported to possess antifungal and antibacterial properties, making it a potential candidate for use in medical and agricultural applications. DMOM is also known to be an intermediate in the synthesis of isoxazolyl-containing compounds, which have various industrial and medicinal uses.
Check Digit Verification of cas no
The CAS Registry Mumber 19788-36-4 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 1,9,7,8 and 8 respectively; the second part has 2 digits, 3 and 6 respectively.
Calculate Digit Verification of CAS Registry Number 19788-36:
(7*1)+(6*9)+(5*7)+(4*8)+(3*8)+(2*3)+(1*6)=164
164 % 10 = 4
So 19788-36-4 is a valid CAS Registry Number.
InChI:InChI=1/C6H9NO2/c1-4-6(3-8)5(2)9-7-4/h8H,3H2,1-2H3
19788-36-4Relevant articles and documents
COMPOUNDS, COMPOSITIONS AND METHODS FOR HISTONE LYSINE DEMETHYLASE INHIBITION
-
Paragraph 0737; 0811, (2022/03/09)
The present disclosure relates generally to compounds and pharmaceutical compositions for the selective inhibition of histone lysine demethylase5 (KDM5), particularly KDM5B, and methods of their use in treating conditions and diseases associated with KDM5 activity.
COMPOUNDS AND METHODS
-
Page/Page column 71, (2013/03/26)
The present invention relates to novel retinoid-reiated orphan receptor gamma (RORy) modulators and their use in the treatment of diseases mediated by RORy.
COMPOUNDS AND METHODS
-
Page/Page column 26, (2013/03/26)
The present invention relates to no vel retinoid-related orphan receptor gamma (RQRy) modulators and their use in the treatment of diseases mediated by RORy.